In both olaparib- and paclitaxel-treated ovarian cancer cells, verapamil and elacridar MDR1 inhibitors can reverse ABCB1-mediated drug resistance, but the clinical trial outcome is poor. This evidence concerns the gene ABCB1 and ovarian carcinoma.